The niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice

Endocrinology

Volumn 155, Issue 8, 2014, Pages 2810-2819

  Sugizaki, Taichi ^a   Watanabe, Mitsuhiro ^a,b   Horai, Yasushi ^a   Kaneko Iwasaki, Nao ^a   Arita, Eri ^a   Miyazaki, Teruo ^c   Morimoto, Kohkichi ^a   Honda, Akira ^c   Irie, Junichiro ^a   Itoh, Hiroshi ^a  

^a Institute for Advanced Medical Research   (Japan)

^b Keio University Shonan Fujisawa Campus   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CELLS, CULTURED; DIET, HIGH-FAT; FATTY LIVER; GLUCOSE METABOLISM DISORDERS; HEPATOCYTES; INTESTINES; LIPID METABOLISM; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, OBESE; ORPHAN NUCLEAR RECEPTORS; RATS; RATS, SPRAGUE-DAWLEY; STEAROYL-COA DESATURASE;

EID: 84905020959     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-2143     Document Type: Article

References (43)

1. Nesto R. CHD: a major burden in type 2 diabetes. Acta Diabetol. 2001; 38 Suppl 1:S3-S8.
2. Wang Y, Yu Q, Fan D, Cao F. Coronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies. Expert Rev Cardiovasc Ther. 2012; 10:1051-1060.
3. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303:1201-1204.
4. Davis HR Jr, Hoos LM, Tetzloff G, et al. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/-mice. Arterio-scler Thromb Vasc Biol. 2007; 27:841-849.
5. Labonte ED, Camarota LM, Rojas JC, et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1 -/- mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295:G776-G783.
6. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007; 581:5664-5670.
7. Hiramitsu S, Ishiguro Y, Matsuyama H, et al. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb. 2010; 17:106-114.
8. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009; 106:15430-15435.
9. Petruzzelli M, Lo Sasso G, Portincasa P, Palasciano G., Moschetta A. Targeting the liver in the metabolic syndrome: evidence from animal models. Curr Pharm Des. 2007; 13:2199-2207.
10. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab. 2009; 297:E1030-E1038.
11. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439:484-489.
12. Honda A, Miyazaki T, Ikegami T, et al. Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS/ MS. J Steroid Biochem Mol Biol. 2010; 121:556-564.
13. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2002; 105:2867-2871.
14. Kajiyama Y, Ui M. Switching from alpha 1-to beta-subtypes in adrenergic response during primary culture of adult-rat hepatocytes as affected by the cell-to-cell interaction through plasma membranes. Biochem J. 1994; 303:313-321.
15. Beltowski J. Liver X receptors (LXR) as therapeutic targets in dys-lipidemia. Cardiovasc Ther. 2008; 26:297-316.
16. Leyton J, Drury PJ, Crawford MA. Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat. Br J Nutr. 1987; 57:383-393.
17. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007; 22 Suppl 1:S20-S27.
18. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxi-dative stress. Prog Lipid Res. 2003; 42:318-343.
19. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001; 281:G1135-G1139.
20. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stressinobesity and its impact onmetabolic syndrome. J Clin Invest. 2004; 114:1752-1761.
21. Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol. 2008; 19:248-256.
22. Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol Scand Suppl. 2006; 185:33-42.
23. Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c)byoxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000; 14:2819-2830.
24. Kim HJ, Miyazaki M, Ntambi JM. Dietary cholesterol opposes PUFA-mediated repression of the stearoyl-CoA desaturase-1 gene by SREBP-1 independent mechanism. J Lipid Res. 2002; 43:1750-1757.
25. Miyazaki M, Kim YC, Ntambi JM. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res. 2001; 42:1018-1024.
26. Landau JM, Sekowski A, Hamm MW. Dietary cholesterol and the activity of stearoyl CoA desaturase in rats: evidence for an indirect regulatory effect. Biochim Biophys Acta. 1997; 1345:349-357.
27. Cohen P, Miyazaki M, Socci ND, et al. Role for stearoyl-CoA de-saturase-1 in leptin-mediated weight loss. Science. 2002; 297:240-243.
28. Matsuzaka T, Shimano H, Yahagi N, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med. 2007; 13:1193-1202.
29. Kohjima M, Enjoji M, Higuchi N, et al. The effects of unsaturated fatty acids on lipid metabolism in HepG2 cells. In Vitro Cell Dev Biol Anim. 2009; 45:6-9.
30. Schattenberg JM, Wang Y, Singh R, Rigoli R.M., Czaja MJ. Hepa-tocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem. 2005; 280:9887-9894.
31. Cury-Boaventura MF, Curi R. Regulation of reactive oxygen species (ROS) production by C18 fatty acids in Jurkat and Raji cells. Clin Sci (Lond). 2005; 108:245-253.
32. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004; 40:185-194.
33. Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal. 2007; 9:343-353.
34. Ecker J, Liebisch G, Patsch W, Schmitz G. The conjugated linoleic acid isomer trans-9, trans-11 is a dietary occurring agonist of liver X receptor alpha. Biochem Biophys Res Commun. 2009; 388:660-666.
35. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 1998; 93:693-704.
36. Harada LM, Carrilho AJ, Oliveira HC, Nakandakare E.R., Quintao EC. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lo-vastatin) that lower plasma cholesterol. Clin Exp Pharmacol Physiol. 2006; 33:1209-1215.
37. Sandhya VG, Rajamohan T. Comparative evaluation of the hypo-lipidemic effects of coconut water and lovastatin in rats fed fat-cholesterol enriched diet. Food Chem Toxicol. 2008; 46:3586-3592.
38. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375:735-742.
39. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell. 2012; 151:138-152.
40. Takase H, Dohi Y, Okado T, Hashimoto T., Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest. 2012; 42:1287-1294.
41. Tsunoda T, Nozue T, Yamada M, Mizuguchi I., Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013; 100:46-52.
42. Hiramitsu S, Miyagishima K, Ishii J., et al. Effect of ezetimi be on lipid and glucose metabolism after a fat and glucose load. J Cardiol. 2012; 60:395-400.
43. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation. 2007; 30:230-235.